

## Review

## Strategies for the CRISPR-Based Therapeutics

Bin Li,<sup>1,\*</sup> Yuyu Niu,<sup>2,\*</sup> Weizhi Ji,<sup>2,\*</sup> and Yizhou Dong<sup>3,\*</sup>

**The CRISPR (clustered regularly interspaced short palindromic repeats)-based genome editing technology is an emerging RNA-guided nuclease system initially identified from the microbial adaptive immune systems. In recent years, the CRISPR system has been reprogrammed to target specific regions of the eukaryotic genome and has become a powerful tool for genetic engineering. Researchers have explored many approaches to improve the genome editing activity of the CRISPR–Cas system and deliver its components both *ex vivo* and *in vivo*. Moreover, these strategies have been applied to genome editing in preclinical research and clinical trials. In this review, we focus on representative strategies for regulation and delivery of the CRISPR–Cas system, and outline current therapeutic applications in their clinical translation.**

### CRISPR: From a Prokaryotic Immune System to a Genome Editing Tool

In the battle against foreign genetic elements, such as viruses and DNA plasmids, bacteria and archaea have evolved a wide array of immune systems, such as the CRISPR–Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated genes) (see [Glossary](#)) system [1–6]. Many bacteria and archaea possess this unique system to protect themselves from invading viruses and DNA plasmids [5–8]. The microbial CRISPR–Cas system has been extensively used as a genome editing tool because of its ease of use and high precision [1–8]. The CRISPR–Cas system has been divided into two classes: class I with multisubunit Cas effector proteins and class II with a single Cas effector protein [5,6]. Although some class I CRISPR–Cas systems have been reprogrammed for eukaryotic genome editing, their complexity has limited their applications [5,6,9]. The class II systems employ a single Cas protein to fulfill target DNA or RNA cleavage, and show great potential for genome engineering ([Figure 1](#)) [1–6,10,11]. More recently, many new class II CRISPR–Cas systems like Cas12b, Cas12c, Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, and Cas14a have been characterized, expanding the capability of the CRIPSR technology [11–14].

The widely used class II Cas9 and Cas12a (also known as Cpf1) protein recognize and cleave the target double-stranded DNA under the guidance of **guide RNA (gRNA)** ([Figure 1](#)), [1–4,10]. Briefly, gRNA-bound Cas complex [ribonucleoprotein (RNP)] scan targets, recognize the **protospacer adjacent motif (PAM)**, and initiate **R-loop formation** [8]. The process leads to PAM-dependent Cas nuclease activation that generates DNA breaks and eventual DNA repair and genome editing capability [8]. However, there are some differences between the two systems ([Figure 1](#)) [1–4,10]. First, the size of Cas12a and its gRNA is smaller than Cas9's. Second, Cas12a recognizes a PAM sequence of TTTN, whereas the PAM for the Cas9 is NGG. Third, Cas12a makes a staggered cut at a distal site with RuvC and Nuc domains, but Cas9 produces a blunt end directly adjacent to the PAM with RuvC and HNH domains [1–4,10]. Both systems are now increasingly being applied to preclinical studies and clinical trials ([Table 1](#)) for treating severe genetic diseases, cancers, infectious diseases, etc. [15–19]. Later, we mainly focus on multiple therapeutic applications of the Cas9 and Cas12a systems.

### Modulation of the CRISPR System for Improved Genome Editing

On the basis of crystal structure information on the CRISPR–Cas system, many Cas9 and Cas12a variants have been developed to improve the performance of CRISPR-mediated genome editing ([Figure 1](#)) [18,20,21]. For instance, a structure-guided mutagenesis screen is being explored to identify new Cas9 and Cas12a variants with improved DNA specificity or targeting range [18,20,21]. Phage-assisted continuous evolution is also used to rapidly generate Cas9 variants [22]. Evolved Cas9 not only possesses greater DNA specificity than the wild-type Cas9, but also recognizes noncanonical PAMs, such as NG, GAA, and GAT [22]. Moreover, **catalytically inactive Cas (dCas)** variants (dCas9 and dCas12a) have been generated to increase the system's specificity [1,10]. Fusion of deaminases to dCas9 or dCas12a makes it possible to accomplish mutual conversion among four bases, which

### Highlights

The CRISPR–Cas system, an RNA-guided endonuclease, capable of sequence-specific cleavage of target DNA, has been widely used as a genome editing toolbox.

Multiple strategies have been developed to modulate the activity of the CRISPR–Cas system, thus enabling precise control of the CRISPR-mediated genome editing.

The CRISPR–Cas system has been applied to edit the eukaryotic genome both *in vitro* and *in vivo*, and has been intensively investigated in preclinical studies and clinical trials.

The CRISPR-relevant technologies hold tremendous promise in diverse therapeutic applications; however, potential off-target or side effects need to be carefully assessed.

<sup>1</sup>Department of Infectious Disease, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518020, China

<sup>2</sup>Yunnan Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, China

<sup>3</sup>Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA

\*Correspondence:  
libszph@yeah.net, niuyy@lpbr.cn, wji@lpbr.cn, dong.525@osu.edu



expands the potential applications of the CRISPR–Cas system for correcting disease-associated single nucleotide polymorphisms (SNPs) [23–27]. More recently, prime editing has been developed by fusing dCas9 to an engineered reverse transcriptase for genome engineering without introducing double-strand breaks or donor DNA [28].

Both the Cas9 and Cas12a systems have been reprogrammed to cleave targeted DNA sequences by rational design of gRNA sequences, enabling researchers to easily edit DNA sequences [1–4,10]. Introduction of chemical modifications to synthetic gRNA has a critical effect on the activity of the CRISPR–Cas system [29–35]. It has also been found that codelivery of Cas9 mRNA and gRNAs with 2'-O-methyl-3'-phosphorothioate modifications at both termini enhances Cas9-mediated genome editing efficiency from the background level to detectable frequency in multiple human primary cells [29]. Also, the combination of chemically modified Cas12a mRNA and gRNA containing five 2'-fluoro ribose at the 3' terminus augments editing efficiency at least threefold [31,35]. To further improve the potency of Cas9, Yin et al. [32] and Finn et al. [33], respectively, constructed gRNAs with massive modifications at hairpins. When codelivered with Cas9 mRNA, these modified gRNAs induce dramatic knockout of serum protein encoded by the edited gene in the mouse liver [32,33]. Additionally, modification of the 5'-triphosphate group of *in vitro* transcribed gRNA with phosphatase reduces T cell-mediated immune response [36]. Apart from chemical modifications, engineering of the secondary structure of gRNA has been reported to enhance the CRISPR efficiency or specificity (Figure 1) [37–44]. Truncation of gRNA, partial DNA replacement, and 5' hairpin addition has led to remarkable improvement in the CRISPR specificity [37–39]. Additionally, extension of either end of the Cas12a gRNA and optimization of the hairpin structure are two important strategies to enhance on-target activity of the CRISPR–Cas12a system [40–44].

Repair of the CRISPR-induced double-stranded breaks (DSBs) involves two types of pathways, including homology-directed repair (HDR) and nonhomologous end joining (NHEJ) (Figure 1). A series of biological molecules have been found to increase the CRISPR-mediated HDR efficiency, the process that is desired for efficient gene knockin [45–48]. These HDR enhancers include the β3-adrenergic receptor agonist L755507 [45], the protein transport inhibitor brefeldin A [45], ligase IV inhibitors Scr7 [46,47], E1B55K, and E4orf6 [47], kinase inhibitors VE-822 and AZD-7762 [48], and so on. Among them, Scr7 dramatically promotes the HDR efficiency in both cells and mice [46]. The improved efficiency might be attributed to the inhibitory effects of HDR enhancers towards NHEJ [45–48]. By contrast, repair with NHEJ can cause DNA alterations, including deletions, insertions, and modifications, which is beneficial to gene knockout. Thymidine analogs, such as azidothymidine and trifluridine, were found to increase the CRISPR-mediated NHEJ knockout efficiency by impairing the HDR pathway [45].

## Delivery of the CRISPR Components

*Ex vivo* and *in vivo* genome editing are two approaches for the CRISPR-mediated therapy in clinical development (Figure 2), where the CRISPR components can be delivered into mammalian cells in the form of DNA, RNA, or RNP [49,50]. However, delivery of the CRISPR components is one of the challenges to overcome for successful clinical applications of the CRISPR technologies [49–51]. In most current clinical trials, electroporation remains one of the most commonly used methods for delivery of CRISPR *ex vivo* genome editing [49–51]. In recent years, new electroporation-based technologies, such as electroporation of mouse zygotes with preassembled Cas9 RNP complex (CRISPR-EZ) and combination of adeno-associated virus (AAV)-mediated donor infection with Cas9 RNP electroporation (CRISPR-READI), have been developed to codeliver the CRISPR components [52,53]. CRISPR-EZ causes 88% gene disruption and 42% HDR-mediated editing [52]. Further optimization of electroporation conditions enables complete gene disruption and up to 62.5% HDR efficiency [52]. CRISPR-READI allows site-specific integration of AAV donors with lengths up to 4.9 kb [53].

In the case of systemic delivery *in vivo*, multiple factors, including absorption, distribution, metabolism, and excretion (ADME), need to be carefully studied in order to ensure effective and safe

## Glossary

**Catalytically inactive Cas (dCas) variants:** Cas variants retain DNA-binding affinity without their cleavage activity.

**CRISPR–Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated genes):** the CRISPR–Cas refers to both the CRISPR locus and an array of the CRISPR-associated genes (*cas*) located in the genomes of bacteria and archaea. The CRISPR locus consists of short repeated sequences separated by spacers, which is transcribed and processed into guide RNA (gRNA) that can direct Cas nucleases encoded by *cas* genes to recognize and cut target nucleic acid sequences.

**Electroporation:** a physical approach that is being widely explored for delivery of exogenous nucleic acids into a variety of cell types *ex vivo*, especially hard-to-transfect cells, due to the increased cell permeability induced by controlled electrical pulses.

**Guide RNA (gRNA):** the CRISPR–Cas system is directed by the CRISPR RNA (crRNA) or a base-paired precursor crRNA and trans-activating crRNA (tracrRNA). To simplify the dual RNA components, crRNA and tracrRNA are truncated and connected via a loop to form a single gRNA.

**Hematopoietic stem and progenitor cells (HSPCs):** cells that possess the ability to self-renew and differentiate into blood cells.

**Homology-directed repair (HDR):** a DNA repair pathway that repairs double-stranded DNA breaks (as caused by the CRISPR–Cas system) in the presence of a homologous DNA sequence. This repair process leads to targeted gene replacement.

**Induced pluripotent stem cells (iPSCs):** cells, derived from non-pluripotent adult cells, possess embryonic stem cell-like properties.

**Intravitreous injection:** an administration route via the vitreous of the eye.

**Nonhomologous end joining (NHEJ):** a DNA repair pathway that repairs double-stranded DNA breaks in the absence of a homologous DNA sequence. Repair with NHEJ can cause DNA

genome editing in target cells and organs. Moreover, when selecting delivery vehicles for the CRISPR system, the delivery strategy should match the need of specific diseases. An appropriate *in vivo* delivery method should possess favorable pharmaceutical profiles, like high delivery efficiency, high tissue specificity, and low side effects [49]. AAVs are the most commonly used viral vectors for CRISPR delivery *in vivo* [54]. AAV serotypes<sup>i</sup> with different tropisms have the ability to target different organs [54]. Apart from AAVs, lentivirus has also been explored for CRISPR delivery in preclinical studies [51,55].

Recently, a number of biomaterials, such as lipid, polymeric, and inorganic nanoparticles (NPs), have been developed for transient expression of the CRISPR systems *in vivo* [49,50,56]. For example, zwitterionic amino lipid, ZA3-Ep10, has been formulated for codelivery of Cas9 mRNA and gRNA in mice [57]. *In vivo* bioluminescence imaging indicates that ZA3-Ep10 NPs mainly distribute in the lung (Figure 2) [57]. Cationic lipid-assisted NPs (CLANs) have been constructed as NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome-targeting vehicles in order to deliver Cas9 mRNA and gRNA to inflammasome in macrophages (Figure 2) [58]. Intravenous injection of CLANs containing Cas9 mRNA and gRNA targeting NLRP3 alleviates NLRP3-dependent acute inflammation and adipose inflammation in mouse models [58]. Furthermore, PEGylated helical polypeptide nanoparticles (P-HNPs) loaded with Cas9 plasmid- and gRNA targeting polo-like kinase 1 have displayed more than 71% tumor inhibition efficacy in HeLa xenograft tumor-bearing mice [59]. Recent studies have shown that the CRISPR–Gold NPs, composed of Cas9 RNP, gold nanoparticles, DNA, and cationic polymers, not only mediate genome editing in neurons, astrocytes, and microglia, but also alleviate the exaggerated repetitive behaviors of fragile X syndrome by reduction of the metabotropic glutamate receptor 5 (mGluR5) protein in the brain striatum of a mouse model with an intracranial injection (Figure 2) [60]. Meanwhile, CRISPR–Gold NPs enable local delivery of the CRISPR for treating muscle degeneration disease (Figure 2) [61]. Collectively, these biomaterials represent promising delivery platforms for effective *in vivo* genome editing.

## Ex Vivo Therapeutic Applications of the CRISPR System

As stated earlier, ex vivo remains the mainstream method for the CRISPR-based therapeutics in current clinical translations (Table 1). Editing of hematopoietic stem and progenitor cells (HSPCs) with the CRISPR–Cas system provides a potential treatment option for hematological diseases, as evidenced by preclinical and clinical studies [62–65]. CTX001, a CRISPR-mediated autologous HSPCs therapy, is currently in a Phase I/II clinical trial for the treatment of severe sickle cell disease and transfusion-dependent β-thalassemia ([ClinicalTrials.gov](#) identifier: NCT03745287 and NCT03655678, Table 1). Preclinical studies show that disruption of the *BCL11A* erythroid enhancer with the CRISPR technology increases therapeutic levels of fetal hemoglobin [64]. This strategy can also be used to restore globin chain balance of hematopoietic stem cells with β-thalassemia [64]. For sickle cell disease, the CRISPR-mediated genome editing of the mutation in the β-globin gene in patient-derived HSPCs not only effectively reduces the number of sickle cells, but also induces stable expression of normal hemoglobin in mice post-transplantation [63]. In addition to hematological diseases, CRISPR-mediated gene editing of HSPCs is applicable to **X-linked chronic granulomatous disease (X-CGD)**. Electroporation of Cas9 mRNA, gRNA targeting the *CYBB* gene, and single-stranded DNA template into CD34+ HSPCs from X-CGD patients enables more than 20% reparation of the mutant *CYBB* gene. Moreover, production of functional mature human myeloid and lymphoid cells lasts up to 5 months when corrected X-CGD HSPCs are transplanted into mouse models [62].

In addition, ex vivo genome editing of induced pluripotent stem cells (iPSCs) holds promise for the treatment of Duchenne muscular dystrophy (DMD), a severe muscle-degenerative disease caused by small deletions, exon duplications, or loss of exons in the dystrophin gene [66]. Different strategies are needed for different types of mutations. Electroporation of DMD patient-derived iPSCs with CRISPR–Cas9 system for exon knockin is a useful strategy for correcting iPSCs from DMD patients who suffer from loss of exons in the dystrophin gene [66]. Full-length dystrophin protein expression

alterations, including deletions, insertions, and modifications.


**Orphan disease:** also called rare disease. The incidence of such disease is low in the population (<200 000 people in the USA).

**Protospacer adjacent motif (PAM):** a short and specific DNA sequence adjacent to the target DNA region (protospacer), which is required for target DNA recognition and cleavage by Cas endonuclease.

**R-loop:** a triple-stranded structure comprises a gRNA–DNA hybrid and a DNA strand which is paired with the DNA strand in the hybrid before unwinding.

**Subretinal injection:** an administration route via the subretinal space of the eye.

**X-linked chronic granulomatous disease (X-CGD):** a chronic immunodeficiency disease caused by mutations in the *CYBB* gene.

**Figure 1. Modulations of the CRISPR–Cas9 and CRISPR–Cas12a Systems.**

Cas (CRISPR-associated) and guide RNA (gRNA) variants have been created to modulate the CRISPR system with improved efficiency, specificity, or altered protospacer adjacent motif (PAM). Biological molecules can regulate double-stranded breaks (DSBs) repair pathways after the CRISPR–Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated genes)-mediated genome editing. CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) of the CRISPR–Cas9 system can be truncated and connected via a loop to form a single gRNA. The RuvC and HNH domains of Cas9 are indicated with green symbols. For the CRISPR–Cas12a system, crRNA is also called gRNA in some cases. The RuvC and Nuc domains of Cas12a are indicated with gray symbols. Abbreviations: HDR, homology-directed repair; NHEJ, nonhomologous end joining; NTS, nontarget strand; TS, target strand.

**Table 1. The CRISPR-Based Therapy in Clinical Trials<sup>a</sup>**

Target gene	Disease indication	Delivery system	Phase	Status	ClinicalTrials.gov identifier <sup>i</sup>	Sponsor
<i>BCL11A</i>	Sickle cell disease, hematological diseases, emoglobinopathies	Infusions of CRISPR–Cas9 treated autologous CD34+ HSPCs (CTX001) (ex vivo)	Phase I/II	Recruiting	NCT03745287	Vertex Pharmaceuticals Incorporated, USA
<i>BCL11A</i>	β-thalassemia, thalassemia, genetic diseases, inborn hematologic diseases, hemoglobinopathies	Infusions of CRISPR–Cas9 treated autologous CD34+ HSPCs (CTX001) (ex vivo)	Phase I/II	Recruiting	NCT03655678	Vertex Pharmaceuticals Incorporated, USA
<i>CEP290</i>	Leber congenital amaurosis type 10	Subretinal injection of AGN-151587 (EDIT-101) ( <i>in vivo</i> )	Phase I/II	Recruiting	NCT03872479	Allergan, USA
Unknown	B cell malignancy, non-Hodgkin lymphoma, B cell lymphoma	Infusions of CRISPR–Cas9 treated CD19-directed T cells (CTX110) (ex vivo)	Phase I/II	Recruiting	NCT04035434	CRISPR Therapeutics AG, USA
TCR and <i>B2M</i>	B cell leukemia, B cell lymphoma	Infusions of CRISPR–Cas9 treated CD19-directed chimeric antigen receptor T (CAR T) cells (UCART019) (ex vivo)	Phase I/II	Recruiting	NCT03166878	Chinese PLA General Hospital, China
Unknown	B cell leukemia, B cell lymphoma	Infusions of CRISPR–Cas9 treated CD19- and CD20- (or CD19- and CD22-) directed CAR T cells (ex vivo)	Phase I/II	Recruiting	NCT03398967	Chinese PLA General Hospital, China
<i>PD-1</i>	Gastric carcinoma, nasopharyngeal carcinoma, T cell lymphoma, adult Hodgkin lymphoma, diffuse large B cell lymphoma	Infusions of CRISPR–Cas9 treated cytotoxic T lymphocytes (ex vivo)	Phase I/II	Recruiting	NCT03044743	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, China
<i>HPV E6/E7</i>	HPV-related cervical intraepithelial neoplasia	Plasmid in gel ( <i>in vivo</i> )	Phase I	Not yet recruiting	NCT03057912	First Affiliated Hospital, Sun Yat-Sen University, China
<i>PD-1</i> and TCR	Solid tumor, adult	CRISPR–Cas9 treated CAR T cell infusions (ex vivo)	Phase I	Recruiting	NCT03545815	Chinese PLA General Hospital, China
<i>PD-1</i> and TCR	Multiple myeloma, melanoma, synovial sarcoma, myxoid/round cell liposarcoma	Infusions of CRISPR–Cas9-treated autologous T cells (ex vivo), combined with chemotherapy agents	Phase I	Recruiting	NCT03399448	University of Pennsylvania, USA
<i>HPK1</i>	CD19-positive leukemia, lymphoma	Infusions of CRISPR–Cas9-treated autologous CD19-directed T cells (transfection with a lentiviral vector and electroporation) (ex vivo)	Phase I	Recruiting	NCT04037566	Xijing Hospital, China
<i>PD-1</i>	Solid tumor, adult	CRISPR–Cas9-treated CAR T cell infusions (ex vivo)	Phase I	Recruiting	NCT03747965	Chinese PLA General Hospital, China

(Continued on next page)

**Table 1. Continued**

Target gene	Disease indication	Delivery system	Phase	Status	ClinicalTrials.gov identifier <sup>i</sup>	Sponsor
PD-1	Metastatic non-small cell lung cancer	Infusions of CRISPR–Cas9-treated T cells (ex vivo)	Phase I	Active, not recruiting	NCT02793856	Sichuan University, China
CD7	T cell malignancies	Infusions of CRISPR–Cas9 treated CD7-specific CAR T cells (ex vivo)	Phase I	Not yet recruiting	NCT03690011	Baylor College of Medicine
HBB	Thalassemia	Infusions of CRISPR–Cas9-treated induced hematopoietic stem cells (ex vivo)	Early phase I	Not yet recruiting	NCT03728322	Allife Medical Science and Technology Co., Ltd, China
CCR5	HIV-1-infection	Transplantation of CRISPR–Cas9-treated CD34+ HSPCs (ex vivo)	Not applicable	Recruiting	NCT03164135	Affiliated Hospital to Academy of Military Medical Sciences, China
KMT2D	Kabuki syndrome 1	Unknown (ex vivo)	Not applicable	Active, not recruiting	NCT03855631	University Hospital, Montpellier, France
PD-1	Esophageal cancer	Infusions of CRISPR–Cas9-treated T cells (ex vivo)	Not applicable	Completed	NCT03081715	Hangzhou Cancer Hospital, China
NF1	Neurofibromatosis type 1 with tumors of the central nervous system	Unknown (ex vivo)	Not applicable	Completed	NCT03332030	Children's Research Institute, USA
KMT2D	Kabuki syndrome 1	Unknown (ex vivo)	Not applicable	Active, not recruiting	NCT03855631	University Hospital, Montpellier, France

<sup>a</sup>The information is from ClinicalTrials.gov<sup>ii</sup>, accessed in November 2019.


can be detected after DMD patient-derived iPSCs are corrected and differentiated into skeletal muscle cells [66]. Similar outcomes are observed when the CRISPR-based deletion strategy is utilized to restore the reading frame of DMD patient-derived iPSCs with frameshift mutations [67]. After engrafting these iPSCs into the animal model of DMD, these cells result in the functional dystrophin glycoprotein complex *in vivo* [67].

CRISPR-based ex vivo therapeutics have also been applied to other **orphan diseases**. For example, recessive dystrophic epidermolysis bullosa (RDEB), a rare hereditary skin disorder, is caused by mutations in the gene of COL7A1-encoding type VII collagen [68]. Grafting of ex vivo CRISPR-edited RDEB keratinocytes or fibroblasts onto immunodeficient mice leads to functional collagen VII expression and right localization [68,69]. Another example of application of CRISPR-based therapeutics in orphan diseases is in hereditary tyrosinemia type 1, a rare metabolic disease. Recent studies show that transplantation of the CRISPR-edited hepatocytes improves the metabolic liver injury caused by the disease [70,71].

## In Vivo Therapeutic Applications of the CRISPR System

### Muscle Degeneration Disease

One of the most successful examples of *in vivo* applications of CRISPR is in the muscle degeneration disease DMD (Figure 2). In 2016, three separate studies described use of AAV9-mediated CRISPR–Cas9 technology to treat DMD in mouse models [72–74]. Although distinct administration routes, including intraperitoneal, intramuscular, and systemic administration, were employed to deliver the CRISPR–Cas9 using AAV9 vectors, researchers were able to detect corrected dystrophin expression, and thereby partially recover skeletal or cardiac muscle function in the mouse model of DMD



**Figure 2. Graphic Overview of the CRISPR-Based Ex Vivo and In Vivo Therapeutics.**

The CRISPR (clustered regularly interspaced short palindromic repeats) systems can be delivered *ex vivo* and *in vivo* by physical methods, viral vectors, biomaterials, or their combinations. The pink broken circle indicates procedures for the CRISPR-mediated genome editing *ex vivo*. The light green circle indicates *in vivo* therapeutic applications of the CRISPR system. BAMEA-O16B, C12-200, LNP-INT01, and TT3 are lipid nanoparticles. Abbreviations: AAV, adeno-associated virus; CLANS, cationic lipid-assisted nanoparticles; ZA3-Ep10, zwitterionic amino lipid.

[72–74]. The common strategy among these studies is to correct the point mutation in exon 23 of the mouse model of DMD [72–74]. Recently, Min *et al.* reported that AAV9–Cas9-mediated correction of exon 44 deletion mutations is also an efficient strategy for the treatment of DMD in human cells and transgenic mice harboring the same deletion mutation [75,76].

### Eye-Related Genetic Diseases

In early 2019, a single ascending dose clinical trial (Phase I/II, [ClinicalTrials.gov](#) identifier: NCT03872479, [Table 1](#)) was initiated for the treatment of Leber congenital amaurosis type 10 (LCA10), a retinal degenerative disease caused by a mutation in the CEP290 gene. Preclinical studies show that **subretinal injection** of EDIT-101 (also called AGN-151587, [Table 1](#)), AAV5 packaged CRISPR–Cas9, restores vision loss in humanized CEP290 mice [77]. In addition, vascular endothelial growth factor receptor 2 (VEGFR2) is an important therapeutic target for angiogenesis-associated diseases, such as proliferative diabetic retinopathy and neovascular age-related macular degeneration [78]. To disrupt genomic VEGFR2 locus, a recent work uses recombinant AAV1 to pack Cas9 and gRNA [78]. **Intravitreal injection** of AAV1-mediated Cas9/gRNA leads to remarkable elimination of angiogenesis, as demonstrated in two mouse models of eye diseases: oxygen-induced retinopathy and laser-induced choroid neovascularization ([Figure 2](#)) [78]. This study suggests that AAV1-mediated CRISPR–Cas9 targeting aberrant VEGFR2 gene not only inhibits pathological angiogenesis in mouse models, but also provides a method for the treatment of other VEGF-induced neovascularization, like inhibiting tumor growth and tumor metastasis by reduction of the formation of angiogenesis. Furthermore, to edit angiogenesis-associated vascular endothelial growth factor A (Vegfa) and hypoxia inducible factor 1a (Hif1a) genes, DNA sequences encoding Cas12a and CRISPR RNA (crRNA) targeting Vegfa and Hif1a are incorporated into an AAV9 vector. A single intravitreal administration of these AAV into the mouse retina gives rise to a long-term reduction of the area of laser-induced choroidal neovascularization [79].

### Liver-Related Genetic Diseases

Gene correction of pathogenic mutations in the liver with the CRISPR systems offers a treatment option for liver-related genetic diseases, such as hereditary tyrosinemia. Systemic delivery of Cas9 mRNA with C12-200 lipid NPs and gRNA/HDR template with AAV vector is capable of correcting 6% of hepatocytes in a mouse model of human hereditary tyrosinemia (Figure 2) [80]; another example is alpha-1 antitrypsin (AAT) deficiency (AATD). Delivery of dual AAV vectors expressing Cas9 and gRNA/HDR template into mouse models of AATD is able to correct mutant allele in the liver and restore serum AAT levels to within normal range (Figure 2) [81]. Proprotein convertase subtilisin/kexin type 9 (PCSK9), related to hypercholesterolemia, plays an important role in metabolism of the low-density lipoprotein. Administration of Cas9/gRNA packaged in AAV2/8, targeting the *Pcsk9* gene in the mouse liver with AAV titer of  $0.5 \times 10^{11}$  to  $4 \times 10^{11}$ , leads to significant decreases in the levels of both PCSK9 and total cholesterol in mice for a month (Figure 2) [82].

Several groups have also developed biomaterials to deliver the CRISPR components to the liver [83,84]. For instance, TT3 and BAMEA-O16B are lipid NPs used for systemic codelivery of Cas9 mRNA and gRNA to the mice liver, effectively allowing *Pcsk9* gene editing and downregulation of Pcsk9 protein level (Figure 2) [83–85]. LNP-INT01 is also a lipid NP that can be used for CRISPR delivery to the liver to treat transthyretin amyloidosis [33]. Administration of single dosed LNP-INT01 containing Cas9 mRNA and chemically modified gRNA targeting the transthyretin (*Ttr*) gene in the mouse liver decreases over 97% of serum TTR protein in both mice and rats. Moreover, the low systemic TTR levels continue to be observed for at least one year (Figure 2) [33].

### Cancers

NP-mediated delivery of the CRISPR system has also shown potential for cancer therapy. Codelivery of the CRISPR system and paclitaxel (an anticancer drug) to tumor tissues with R8-dGR (a cell penetrating peptide)-modified cationic liposome is capable of inhibiting the metastasis of pancreatic tumor cells and prolonged survival time without inducing severe toxicity [85]. Encapsulating plasmids, encoding Cas9 and gRNA targeting VEGFA into a lipopolymer, display tumor targeting properties [86]. Intravenous administration of this formulation results in significant accumulation in the tumor, thus effectively inhibiting osteosarcoma malignancy and lung metastasis by downregulation of the angiogenesis [86]. Targeting of oncogenes using the CRISPR technology is another possible method for the treatment of cancer [87]. Editing of endogenous activated oncogenes, such as epidermal growth factor receptor (*EGFR*), *HRAS*, and *BRAF* that are recurrently found in various cancer types, via the CRISPR–Cas9, may disrupt gain-of-function mutations [87]. Similar concepts have been applied to target the viral oncogenes. For instance, the CRISPR-mediated disruption of human papillomavirus (HPV) E6 and/or E7 oncogene, responsible for cervical cancer, is currently in a phase I clinical trial (ClinicalTrials.gov identifier: NCT03057912, Table 1) [87].

### Concluding Remarks and Future Perspectives

The bacteria derived CRISPR–Cas system enables precise and effective genome engineering in eukaryotic organisms. Recent developments in the CRISPR technology have witnessed continuous progress in the field of genome editing. Rational design of the CRISPR delivery platforms make it possible to achieve tissue-specific genome editing *in vivo*. A number of CRISPR-based *ex vivo* and *in vivo* therapeutics are currently in clinical trials (Table 1). Moreover, the structure-guided mutagenesis screening or directed evolution of the CRISPR–Cas system results in next-generation Cas endonucleases with enhanced target specificity and expanded targeting ranges [18].

While massive advances have been made to facilitate clinical translations of the CRISPR, there are some limitations that need to be solved before the CRISPR technology becomes a prevailing genome editing tool for modern medicine (see Outstanding Questions) [18,19,88]. Systemic delivery of the CRISPR components remains a key challenge. Many types of cells, such as neurons, cardiomyocytes, and immune cells, demand *in vivo* delivery vehicles for efficient genome editing; another concern is to minimize off-target effects (undesired genome editing in other gene loci) of the system, so as to prevent large deletions and complex rearrangements [89]. Standard and quantitative methods should be

established to analyze the genome editing data. Additionally, clinical translation of the CRISPR system may encounter multiple concerns, such as the p53-mediated response of DNA damage [90,91] and pre-existing antibodies to Cas proteins [92–94]. Comprehensive studies are needed to carefully assess the impact of these findings. By gaining more insights from preclinical and clinical data, researchers and clinicians will have a profound understanding of the CRISPR system; with this new knowledge and experience, we envisage that the CRISPR technology may be exploited to treat a broad range of human diseases in the future.

## Acknowledgments

Y.N. and W.J. acknowledge the National Key Research and Development Program (2016YFA0101401). Y.D. acknowledges the support of the Maximizing Investigators' Research Award R35GM119679 from the National Institute of General Medical Sciences.

## Resources

<sup>i</sup>[www.addgene.org/guides/aav/](http://www.addgene.org/guides/aav/)

<sup>ii</sup><https://clinicaltrials.gov/>

## References

1. Jinek, M. et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 337, 816–821
2. Gasiunas, G. et al. (2012) Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc. Natl. Acad. Sci. U. S. A.* 109, E2579–E2586
3. Cong, L. et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science* 339, 819–823
4. Mali, P. et al. (2013) RNA-guided human genome engineering via Cas9. *Science* 339, 823–826
5. Makarova, K.S. et al. (2015) An updated evolutionary classification of CRISPR–Cas systems. *Nat. Rev. Microbiol.* 13, 722–736
6. Shmakov, S. et al. (2017) Diversity and evolution of class 2 CRISPR–Cas systems. *Nat. Rev. Microbiol.* 15, 169–182
7. van der Oost, J. et al. (2014) Unravelling the structural and mechanistic basis of CRISPR–Cas systems. *Nat. Rev. Microbiol.* 12, 479–492
8. Chen, J.S. and Doudna, J.A. (2017) The chemistry of Cas9 and its CRISPR colleagues. *Nat. Rev. Chem.* 1, 0078
9. Pickar-Oliver, A. et al. (2019) Targeted transcriptional modulation with type I CRISPR–Cas systems in human cells. *Nat. Biotechnol.* Published online September 23, 2019. <https://doi.org/10.1038/s41587-019-0235-7>
10. Zetsche, B. et al. (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR–Cas system. *Cell* 163, 759–771
11. Shmakov, S. et al. (2015) Discovery and functional characterization of diverse class 2 CRISPR–Cas systems. *Mol. Cell* 60, 385–397
12. Burstein, D. et al. (2017) New CRISPR–Cas systems from uncultivated microbes. *Nature* 542, 237–241
13. Harrington, L.B. et al. (2018) Programmed DNA destruction by miniature CRISPR–Cas14 enzymes. *Science* 362, 839–842
14. Yan, W.X. et al. (2019) Functionally diverse type V CRISPR–Cas systems. *Science* 363, 88–91
15. Chertow, D.S. (2018) Next-generation diagnostics with CRISPR. *Science* 360, 381–382
16. Li, Y. et al. (2019) CRISPR/Cas systems towards next-generation biosensing. *Trends Biotechnol.* 37, 730–743
17. Porteus, M.H. (2019) A new class of medicines through DNA editing. *N. Engl. J. Med.* 380, 947–959
18. Pickar-Oliver, A. and Gersbach, C.A. (2019) The next generation of CRISPR–Cas technologies and applications. *Nat. Rev. Mol. Cell Biol.* 20, 490–507
19. Fellmann, C. et al. (2017) Cornerstones of CRISPR–Cas in drug discovery and therapy. *Nat. Rev. Drug Discov.* 16, 89–100
20. Gao, L. et al. (2017) Engineered Cpf1 variants with altered PAM specificities. *Nat. Biotechnol.* 35, 789–792
21. Kleinstiver, B.P. et al. (2019) Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. *Nat. Biotechnol.* 37, 276–282
22. Hu, J.H. et al. (2018) Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature* 556, 57–63
23. Komor, A.C. et al. (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 533, 420–424
24. Gaudelli, N.M. et al. (2017) Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* 551, 464–471
25. Li, X. et al. (2018) Base editing with a Cpf1–cytidine deaminase fusion. *Nat. Biotechnol.* 36, 324–327
26. Wang, X. et al. (2018) Efficient base editing in methylated regions with a human APOBEC3A–Cas9 fusion. *Nat. Biotechnol.* 36, 946–949
27. Kim, H.S. et al. (2019) Adenine base editors catalyze cytosine conversions in human cells. *Nat. Biotechnol.* 37, 1145–1148
28. Anzalone, A.V. et al. (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature*. Published online October 21, 2019. <https://doi.org/10.1038/s41586-019-1711-4>
29. Hendel, A. et al. (2015) Chemically modified guide RNAs enhance CRISPR–Cas genome editing in human primary cells. *Nat. Biotechnol.* 33, 985–989
30. Rahdar, M. et al. (2015) Synthetic CRISPR RNA–Cas9-guided genome editing in human cells. *Proc. Natl. Acad. Sci. U. S. A.* 112, E7110–E7117
31. Li, B. et al. (2017) Engineering CRISPR–Cpf1 crRNAs and mRNAs to maximize genome editing efficiency. *Nat. Biomed. Eng.* 1, 0066
32. Yin, H. et al. (2017) Structure-guided chemical modification of guide RNA enables potent non-viral *in vivo* genome editing. *Nat. Biotechnol.* 35, 1179–1187

## Outstanding Questions

What would be a gold standard method to assess off-target mutations induced by the CRISPR–Cas system?

How could we rationally design delivery vehicles for the CRISPR–Cas system to address various delivery challenges, including specificity, efficiency, and safety?

How to evaluate the safety of the CRISPR technology in addition to standard clinical toxicity studies?

What would be the appropriate applications of the CRISPR technology in compliance with ethical and social concerns?

33. Finn, J.D. et al. (2018) A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent *in vivo* genome editing. *Cell Rep.* 22, 2227–2235
34. McMahon, M.A. et al. (2018) Chemically modified Cpf1-CRISPR RNAs mediate efficient genome editing in mammalian cells. *Mol. Ther.* 26, 1228–1240
35. Li, B. et al. (2018) Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing. *Nat. Protoc.* 13, 899–914
36. Kim, S. et al. (2018) CRISPR RNAs trigger innate immune responses in human cells. *Genome Res.* 28, 367–373
37. Fu, Y. et al. (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat. Biotechnol.* 32, 279–284
38. Yin, H. et al. (2018) Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. *Nat. Chem. Biol.* 14, 311–316
39. Kocak, D.D. et al. (2019) Increasing the specificity of CRISPR systems with engineered RNA secondary structures. *Nat. Biotechnol.* 37, 657–666
40. Park, H.M. et al. (2018) Extension of the crRNA enhances Cpf1 gene editing *in vitro* and *in vivo*. *Nat. Commun.* 9, 3313
41. Bin Moon, S. et al. (2018) Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3'-overhang. *Nat. Commun.* 9, 3651
42. Lin, L. et al. (2018) Engineering the direct repeat sequence of crRNA for optimization of FnCpf1-mediated genome editing in human cells. *Mol. Ther.* 26, 2650–2657
43. Teng, F. et al. (2019) Enhanced mammalian genome editing by new Cas12a orthologs with optimized crRNA scaffolds. *Genome Biol.* 20, 15
44. Liu, P. et al. (2019) Enhanced Cas12a editing in mammalian cells and zebrafish. *Nucleic Acids Res.* 47, 4169–4180
45. Yu, C. et al. (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. *Cell Stem Cell* 16, 142–147
46. Maruyama, T. et al. (2015) Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* 33, 538–542
47. Chu, V.T. et al. (2015) Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat. Biotechnol.* 33, 543–548
48. Ma, X. et al. (2018) Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells. *Nat. Commun.* 9, 1303
49. Glass, Z. et al. (2018) Engineering the delivery system for CRISPR-based genome editing. *Trends Biotechnol.* 36, 173–185
50. Wang, H.-X. et al. (2017) CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. *Chem. Rev.* 117, 9874–9906
51. Yin, H. et al. (2017) Delivery technologies for genome editing. *Nat. Rev. Drug Discov.* 16, 387–399
52. Modzelewski, A.J. et al. (2018) Efficient mouse genome engineering by CRISPR-EZ technology. *Nat. Protoc.* 13, 1253–1274
53. Chen, S. et al. (2019) CRISPR-READI: efficient generation of knockin mice by CRISPR RNP electroporation and AAV donor infection. *Cell Rep.* 27, 3780–3789
54. Wang, D. et al. (2019) Adeno-associated virus vector as a platform for gene therapy delivery. *Nat. Rev. Drug Discov.* 18, 358–378
55. Wilbie, D. et al. (2019) Delivery aspects of CRISPR/Cas for *in vivo* genome editing. *Acc. Chem. Res.* 52, 1555–1564
56. Wan, T. et al. (2019) Material solutions for delivery of CRISPR/Cas-based genome editing tools: current status and future outlook. *Mater. Today* 26, 40–66
57. Miller, J.B. et al. (2017) Non-viral CRISPR/Cas gene editing *in vitro* and *in vivo* enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. *Angew. Chem. Int. Ed. Engl.* 56, 1059–1063
58. Xu, C. et al. (2018) Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases. *Nat. Commun.* 9, 4092
59. Wang, H.X. et al. (2018) Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. *Proc. Natl. Acad. Sci. U. S. A.* 115, 4903–4908
60. Lee, B. et al. (2018) Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. *Nat. Biomed. Eng.* 2, 497–507
61. Lee, K. et al. (2017) Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA *in vivo* induces homology-directed DNA repair. *Nat. Biomed. Eng.* 1, 889–901
62. De Ravin, S.S. et al. (2017) CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. *Sci. Transl. Med.* 9, eaah3480
63. Park, S.H. et al. (2019) Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. *Nucleic Acids Res.* 47, 7955–7972
64. Wu, Y. et al. (2019) Highly efficient therapeutic gene editing of human hematopoietic stem cells. *Nat. Med.* 25, 776–783
65. Humbert, O. et al. (2019) Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. *Sci. Transl. Med.* 11, eaaw3768
66. Li, H.L. et al. (2015) Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. *Stem Cell Rep.* 4, 143–154
67. Young, C.S. et al. (2016) A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. *Cell Stem Cell* 18, 533–540
68. Izmiryan, A. et al. (2018) Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR/Cas9 and homology-directed repair. *Mol. Ther. Nucleic Acids* 12, 554–567
69. Bonafont, J. et al. (2019) Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing. *Mol. Ther.* 27, 986–998
70. VanLith, C. et al. (2018) Curative ex vivo hepatocyte-directed gene editing in a mouse model of hereditary tyrosinemia type 1. *Hum. Gene Ther.* 29, 1315–1326
71. VanLith, C.J. et al. (2019) Ex vivo hepatocyte reprogramming promotes homology-directed DNA repair to correct metabolic disease in mice after transplantation. *Hepatol. Commun.* 3, 558–573
72. Tabebordbar, M. et al. (2016) *In vivo* gene editing in dystrophic mouse muscle and muscle stem cells. *Science* 351, 407–411
73. Nelson, C.E. et al. (2016) *In vivo* genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science* 351, 403–407
74. Long, C. et al. (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science* 351, 400–403
75. Min, Y.L. et al. (2019) CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion

- mutations in mice and human cells. *Science Adv.* 5, eaav4324
76. Dash, P.K. et al. (2019) Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. *Nat. Commun.* 10, 2753
77. Maeder, M.L. et al. (2019) Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. *Nat. Med.* 25, 229–233
78. Huang, X. et al. (2017) Genome editing abrogates angiogenesis *in vivo*. *Nat. Commun.* 8, 112
79. Koo, T. et al. (2018) CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration. *Nat. Commun.* 9, 1855
80. Yin, H. et al. (2016) Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components *in vivo*. *Nat. Biotechnol.* 34, 328–333
81. Song, C.Q. et al. (2018) *In vivo* genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency. *Hum. Gene Ther.* 29, 853–860
82. Ran, F.A. et al. (2015) *In vivo* genome editing using *Staphylococcus aureus* Cas9. *Nature* 520, 186–191
83. Li, B. et al. (2015) An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery *in vivo*. *Nano Lett.* 15, 8099–8107
84. Jiang, C. et al. (2017) A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and *pcsk9* *in vivo*. *Cell Res.* 27, 440–443
85. Liu, J. et al. (2019) Fast and efficient CRISPR/Cas9 genome editing *in vivo* enabled by bioreducible lipid and messenger RNA nanoparticles. *Adv. Mater.* 31, e1902575
86. Liang, C. et al. (2017) Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. *Biomaterials* 147, 68–85
87. Oppel, F. et al. (2018) Specific targeting of oncogenes using CRISPR technology. *Cancer Res.* 78, 5506–5512
88. Rossant, J. (2018) Gene editing in human development: ethical concerns and practical applications. *Development* 145, dev150888
89. Kosicki, M. et al. (2018) Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* 36, 765–771
90. Haapaniemi, E. et al. (2018) CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* 24, 927–930
91. Ihry, R.J. et al. (2018) p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. *Nat. Med.* 24, 939–946
92. Simhadri, V.L. et al. (2018) Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. *Mol. Ther. Methods Clin. Dev.* 10, 105–112
93. Wagner, D.L. et al. (2019) High prevalence of *Streptococcus pyogenes* Cas9-reactive T cells within the adult human population. *Nat. Med.* 25, 242–248
94. Charlesworth, C.T. et al. (2019) Identification of preexisting adaptive immunity to Cas9 proteins in humans. *Nat. Med.* 25, 249–254